Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

We previously reported interim results of a phase 1 trial in patients with chronic lymphocytic leukemia (CLL) whereby flavopiridol was administered intravenously as a 30-minute bolus followed by 4-hour infusion. We now report full pharmacokinetic (PK) data, correlations of PK with clinical outcomes,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Phelps, Mitch A., Lin, Thomas S., Johnson, Amy J., Hurh, Eunju, Rozewski, Darlene M., Farley, Katherine L., Wu, Di, Blum, Kristie A., Fischer, Beth, Mitchell, Sarah M., Moran, Mollie E., Brooker-McEldowney, Michelle, Heerema, Nyla A., Jarjoura, David, Schaaf, Larry J., Byrd, John C., Grever, Michael R., Dalton, James T.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2009
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2661854/
https://ncbi.nlm.nih.gov/pubmed/18981292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-07-168583
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares